La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Beijing Tiantan Biological Products Croissance future

Future contrôle des critères 2/6

Beijing Tiantan Biological Products devrait augmenter ses bénéfices et son chiffre d'affaires de 18.2% et de 18.2% par an respectivement. Le BPA devrait croître de de 18.9% par an. Le rendement des capitaux propres devrait être 13.1% dans 3 ans.

Informations clés

18.2%

Taux de croissance des bénéfices

18.9%

Taux de croissance du BPA

Biotechs croissance des bénéfices	35.1%
Taux de croissance des recettes	18.2%
Rendement futur des capitaux propres	13.1%
Couverture par les analystes	Good
Dernière mise à jour	15 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Jul 23

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 09

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

May 22

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Mar 16

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Mar 01

Prévisions de croissance des bénéfices et des revenus

SHSE:600161 - Estimations futures des analystes et données financières antérieures (CNY Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	8,497	1,926	1,820	2,495	8
12/31/2025	7,221	1,618	1,589	2,127	8
12/31/2024	6,050	1,353	1,082	1,828	5
3/31/2024	5,110	1,165	1,087	2,242	N/A
12/31/2023	5,180	1,110	1,316	2,394	N/A
9/30/2023	5,371	1,167	1,254	2,515	N/A
6/30/2023	5,062	1,063	341	1,633	N/A
3/31/2023	4,848	1,018	250	1,539	N/A
12/31/2022	4,261	881	-228	1,126	N/A
9/30/2022	4,207	803	-195	1,097	N/A
6/30/2022	4,191	808	-187	1,117	N/A
3/31/2022	3,970	733	-351	918	N/A
12/31/2021	4,112	760	-151	980	N/A
9/30/2021	3,628	700	-241	728	N/A
6/30/2021	3,702	692	-120	640	N/A
3/31/2021	3,535	659	-71	571	N/A
12/31/2020	3,446	639	93	702	N/A
9/30/2020	3,398	641	306	755	N/A
6/30/2020	3,276	601	362	877	N/A
3/31/2020	3,334	611	184	741	N/A
12/31/2019	3,282	611	116	642	N/A
9/30/2019	3,394	580	282	788	N/A
6/30/2019	3,271	563	376	801	N/A
3/31/2019	3,083	531	729	1,028	N/A
12/31/2018	2,931	509	384	678	N/A
9/30/2018	2,929	568	538	767	N/A
6/30/2018	2,671	532	398	590	N/A
3/31/2018	2,485	1,228	8	186	N/A
12/31/2017	2,483	1,173	N/A	138	N/A
9/30/2017	2,362	1,077	N/A	301	N/A
6/30/2017	2,256	1,038	N/A	280	N/A
3/31/2017	2,330	313	N/A	344	N/A
12/31/2016	2,138	257	N/A	433	N/A
9/30/2016	1,756	151	N/A	251	N/A
6/30/2016	1,709	55	N/A	403	N/A
3/31/2016	1,624	-3	N/A	471	N/A
12/31/2015	1,618	10	N/A	473	N/A
9/30/2015	1,545	-88	N/A	384	N/A
6/30/2015	1,567	-46	N/A	382	N/A
3/31/2015	1,723	46	N/A	560	N/A
12/31/2014	1,827	128	N/A	478	N/A
9/30/2014	2,026	291	N/A	748	N/A
6/30/2014	2,018	377	N/A	705	N/A
3/31/2014	1,905	371	N/A	490	N/A
12/31/2013	1,837	372	N/A	566	N/A
9/30/2013	1,827	459	N/A	593	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 600161 ( 18.2% par an) est supérieure au taux d'épargne ( 2.9% ).

Bénéfices vs marché: Les bénéfices de 600161 ( 18.2% par an) devraient croître plus lentement que le marché CN ( 21.9% par an).

Croissance élevée des bénéfices: Les bénéfices de 600161 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 600161 ( 18.2% par an) devrait croître plus rapidement que le marché CN ( 13.4% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 600161 ( 18.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 600161 devrait être faible dans 3 ans ( 13.1 %).

Beijing Tiantan Biological Products Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 11% to CN¥33.90

Recent updates

Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Investor sentiment deteriorates as stock falls 20%

Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued after recent price rise

Price target increased by 11% to CN¥33.90

Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings

Now 21% overvalued after recent price rise

Now 27% overvalued

Full year 2023 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd., Annual General Meeting, May 29, 2024

We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt

Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.67 (vs CN¥0.53 in FY 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.14 in 3Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.075 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from S&P Global BMI Index

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) dropped from FTSE All-World Index (USD)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 3Q 2021)

Now 20% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.12 in 2Q 2021)

Now 20% undervalued

Now 21% undervalued

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021)

Now 24% undervalued after recent price drop

Less than half of directors are independent

Now 20% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.17 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 1Q 2020)

New 90-day low: CN¥36.46

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.50

New 90-day high: CN¥41.95

Beijing Tiantan Biological Products Co., Ltd. announced that it expects to receive CNY 3.34 billion in funding

Third quarter earnings released

New 90-day low: CN¥37.99

First half earnings released

First half earnings released

New 90-day high - CN¥42.80

Beijing Tiantan Biological Products Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance